We know that we have the science to make our drugs
Post# of 72440
We know that we have a term sheet with a potential partner for OM/IBD that should bring in all the upfront money we should need to bring all our drugs to commerciality.
We know that funds are tight and Leo was able to find a family office that was willing to fund all the monies we need to reach commerciality for a number of our indications.
We know that those same funds come at a very hefty charge unless Leo can pay them back within 30 days or so (I am not that clear on the specifics of the current funding scheme) but at the same time it seems that Leo should/could/possibly be able to bring about the first partnership by then so that the funding is not all that costly.
Looks to me like it all boils down to Leo and Dr. B being able to bring a deal to the table within the hoped for 30 day period.
Many of us have quite a bit riding on this investment. To say that we don't have worries about it coming to fruition without heavy dilution to our holdings is crazy, we all have worries. But then again, I believe it is not so much that we will lose our investment as opposed to that the return on our investment won't be in the upper stratosphere as is expected if we do get the deal in the next month. We know we are going to be winners in this investment, the question now is how big of a winner.
I believe even a very strong showing on P results would give the stock price a good shot in the arm that might allow for other financial input that would put less strain on the share count than what we have currently.
Just a thought, but if P results come in great in the very near future, why wouldn't Leo be able to go to some fat cats and take on debt saying that the money would be paid back within 6-9 months at a nice percentage rate with a guaranteed minimum of 50-100% and pay off the recently announced financing for 10s of millions of shares? I'd say paying a $5-10MM loan off by next summer, even with a 50% interest rate or minimum return on investment, should be a breeze and much cheaper to shareholders than a dilution of many, many shares. This is just throwing thoughts against the wall, may be in left field as viewed by those with strong commercial loan backgrounds.
Right now everything is in the hands of mgt. I hope they are sharp enough to get the job done. I also think they did us shareholders no favors in cutting the financing this close.